Naseem Zojwalla
CIK: 0001905871
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Olema Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Feb 2, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectPerformance Stock Options (Right to Buy)
106.3K shares- - Feb 2, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
250K shares- - Dec 23, 2025OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $7.02$351K - Dec 23, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct99.5K shares at avg. $27.66$2.8M - Dec 22, 2025OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct42.8K shares at avg. $15.25$653K - Dec 22, 2025OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct7.2K shares at avg. $7.02$50K - Dec 22, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct100K shares at avg. $28.04$2.8M - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct12.9K shares at avg. $28.93$374K - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct40K shares at avg. $15.25$610K - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct57.1K shares at avg. $28.03$1.6M - Feb 28, 2025OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
205K shares- - Dec 16, 2024OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct14K shares at avg. $4.87$68K - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct320 shares at avg. $9.39$3K - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct14.2K shares at avg. $8.66$123K - Dec 10, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct13.3K shares at avg. $9.37$124K - Dec 9, 2024OLMA
Olema Pharmaceuticals, Inc.
Award(A)Direct52K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 2, 2026 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Performance Stock Options (Right to Buy) | 106,250 | - | - | Direct |
| Feb 2, 2026 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 250,000 | - | - | Direct |
| Dec 23, 2025 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $7.02 | $351,000 | Direct |
| Dec 23, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 99,509 | $27.66 | $2,752,419 | Direct |
| Dec 22, 2025 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 42,818 | $15.25 | $652,975 | Direct |
| Dec 22, 2025 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 7,182 | $7.02 | $50,418 | Direct |
| Dec 22, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 100,000 | $28.04 | $2,804,000 | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 12,921 | $28.93 | $373,805 | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 40,000 | $15.25 | $610,000 | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 57,079 | $28.03 | $1,599,924 | Direct |
| Feb 28, 2025 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 205,000 | - | - | Direct |
| Dec 16, 2024 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 14,000 | $4.87 | $68,180 | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 320 | $9.39 | $3,005 | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 14,202 | $8.66 | $122,989 | Direct |
| Dec 10, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 13,283 | $9.37 | $124,462 | Direct |
| Dec 9, 2024 | OLMA Olema Pharmaceuticals, Inc. | Award(A) | 52,000 | - | $0 | Direct |
1-16 of 16 transactions
About Zojwalla Naseem
Zojwalla Naseem (SEC CIK 0001905871) files insider reports with the SEC as CHIEF MEDICAL OFFICER of Olema Pharmaceuticals, Inc. (OLMA).
Signal8 holds 5 ownership filings by Zojwalla Naseem, all Form 4s, filed between Dec 11, 2024 and Feb 4, 2026. Those filings report 16 transactions, from Dec 9, 2024 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Zojwalla Naseem's filings is in SAN FRANCISCO, CA.
Recent filings by Zojwalla Naseem
- Feb 2, 2026: Grants or awards of OLMA derivative securities (2 lines, Form 4, code A).
- Dec 23, 2025: Option exercise of OLMA shares (Form 4, code M).
- Dec 23, 2025: Open-market sale of OLMA shares (Form 4, code S).
- Dec 22, 2025: Option exercises of OLMA shares (2 lines, Form 4, code M).
- Dec 22, 2025: Open-market sale of OLMA shares (Form 4, code S).
Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)
- O'Byrne Jason, CHIEF FINANCIAL OFFICER
- Harmon Cyrus, Director
- BVF PARTNERS L P/IL, Director
- BUTITTA CYNTHIA M, Director
- Garland J. Scott, Director
- Hrustanovic Gorjan, Director